Terminé

GIFT PilotFeasibility Study of a Randomized Controlled Trial of a Novel Device vs. Intermittent Pneumatic Compression for Prevention of Venous Thromboembolism in Trauma Patients

0 critères remplis à partir de votre profilVoyez en un coup d'œil comment votre profil répond à chaque critère d'éligibilité.
Ce qui est testé

geko

+ IPCs

Dispositif médical
Qui peut participer

Maladies Cardiovasculaires+3

+ Thromboembolie

+ Maladies vasculaires

À partir de 18 ans
Voir tous les critères d'éligibilité
Comment se déroule l'étude

Étude de prévention

Phase 2
Interventionnel
Date de début : juillet 2013
Voir le détail du protocole

Résumé

Sponsor principalHamilton Health Sciences Corporation
Dernière mise à jour : 19 mars 2015
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Date de début de l'étude : 1 juillet 2013

Date à laquelle le premier participant a commencé l'étude.

Trauma patients are at a high risk of developing blood clots in the legs (deep vein thrombosis - DVT), which can travel to the lungs and cause serious health consequences. Often, these patients cannot receive blood-thinning medication to prevent these blood clots because of the risk of bleeding; in this case, they are usually given intermittent pneumatic compression devices (IPCs) to prevent blood clots. IPCs are inflatable sleeves that fit over the legs and periodically inflate and deflate, helping to pump blood out of the legs and thus reduce the risk of blood clot formation. Several studies suggest that IPCs are working properly on the patient only 60-70% of the time. Some patients also find them uncomfortable. A new device (geko) that works by stimulating the leg muscles and increasing blood flow in the legs has recently been developed. To compare the geko with IPCs, this study will randomly assign trauma patients who cannot receive blood thinners for blood clot prevention to either IPCs or geko. The main goal is to determine the feasibility of doing a larger study which would compare the efficacy of these devices in preventing blood clots. The amount of time the devices are properly used on the patients, comfort and tolerability, development of blood clots, and blood flow in the leg veins and arteries will also be measured and compared between the devices.

Sponsor principalHamilton Health Sciences Corporation
Dernière mise à jour : 19 mars 2015
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Protocole

Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.
Détails du design

20 participants à inclure

Nombre total de participants que l'essai clinique vise à recruter.

Prévention

Cette étude cherche à prévenir l'apparition d'une maladie ou d'un trouble chez des personnes qui ne l'ont pas encore développé. Elles concernent souvent des personnes à risque et testent des vaccins, des changements de mode de vie ou des traitements préventifs.



Éligibilité

Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.
Conditions
Critères

Tout sexe

Le sexe biologique des participants éligibles à s'inscrire.

À partir de 18 ans

Tranche d'âge des participants éligibles à participer.

Volontaires sains non autorisés

Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.

Conditions

Pathologie

Maladies CardiovasculairesThromboembolieMaladies vasculairesEmbolie et ThromboseBlessures et lésionsThromboembolie veineuse

Critères

Inclusion Criteria: Diagnosis of trauma, meeting criteria for referral to the HHS trauma service - ANY of the following (1-3): patient with obvious major injuries in two or more systems, each requiring a specialist and inpatient care spinal injury with paraplegia or tetraplegia; severe penetrating injury to the head, neck, trunk or groin; amputation above the wrist or ankle; burns, second or third degree, involving 20% or more body surface area, or involving the face or genitalia Glasgow Coma Scale (GCS) less than or equal to 10, as a result of trauma or any two of: significant decrease in level of consciousness pulse < 50 or > 120 BP < 80 or absent radial pulse Respiratory rate < 10 or > 24 Subject admitted to the Hamilton General Hospital ICU or the hospital ward step-down units Age 18 years or older Contraindication to anticoagulation expected to last for more than 3 days. Contraindication to anticoagulation may include intracranial hemorrhage, ocular injury with associated hemorrhage, solid intra-abdominal organ injury (i.e. liver, spleen, kidney), and/or pelvic or retroperitoneal hematoma requiring transfusion. [12] The final determination of whether anticoagulant prophylaxis is contraindicated will be made by the treating physician. Projected hospitalization greater than 3 days (as determined by treating physician) Informed consent can be provided by the subject or substitute decision maker within 48 hours of admission Exclusion Criteria: Inability to wear either IPCs or gekoTM on both legs, including but not limited to: unstable fracture of the lower extremity; compartment syndrome of the lower extremity; skin breakdown affecting the area on which the devices will be applied; prior amputation affecting the area on which the devices will be applied; severe peripheral ischemic vascular disease; uncontrolled bleeding of the lower extremity; Diagnosis of DVT within 1 month prior to assessment for enrollment Use of anticoagulant medication within 24h of enrollment (except when used solely as a flush for intravenous catheters), or ongoing effect of anticoagulant medication at time of enrollment as determined by history of medication use and laboratory evidence of medication effect. For the purposes of this study, anticoagulant medications include: unfractionated heparin (intravenous or subcutaneous) low molecular weight heparin fondaparinux dabigatran rivaroxaban warfarin argatroban danaparoid lepirudin Leg circumference greater than 24 inches at the location the gekoTM device would be secured to the leg. Presence of cardiac demand pacemaker

Plan de l'étude

Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.
Groupes de traitement
Objectifs de l'étude

2 groupes d'intervention sont désignés dans cette étude

Cette étude ne comporte pas de groupe placebo. 

Groupes de traitement

Groupe I

Expérimental
For subjects randomized to the experimental treatment arm, one gekoTM device will be applied to each leg according to the manufacturer's instructions by the subject's primary care nurse. All nurses applying the devices must be trained on proper application technique. The old devices will be removed and new devices applied daily. The subject will continue to use the devices until he or she exits the study.

Groupe II

Comparateur actif
The control treatment will consist of the hospital's standard IPC devices. The IPCs will be applied to each leg by the subject's primary care nurse according to the manufacturer's instructions. They will continue to be applied until exit from the study. At the time of withdrawal from the study, the decision regarding continued use of IPCs will be made by the treating physician.

Objectifs de l'étude

Objectifs principaux

Objectifs secondaires

Centres d'étude

Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.

Cette étude comporte 1 site

Hamilton General Hospital

Hamilton, CanadaOuvrir Hamilton General Hospital dans Google Maps
Terminé1 Centres d'Étude